An updated pocket card on asthma and COPD inhalers for pharmacy and medical students: inhaler classes, GINA 2026 asthma steps, GOLD COPD treatment, acute attacks, inhaler technique and side effects.
Asthma & COPD Inhalers Pocket Card 2026
Inhaled medicines and treatment steps · based on GINA 2026 and GOLD 2026/2027
Preferred preferred option Alt alternative Avoid avoid | ICS = inhaled corticosteroid · SABA/LABA = short/long-acting beta-agonist · LAMA = long-acting antimuscarinic · MART = maintenance and reliever therapy
Inhaler classes
- SABA (reliever): salbutamol 100-200 mcg as needed; terbutaline
- ICS: beclometasone, budesonide, fluticasone, ciclesonide; rinse mouth after use
- ICS-formoterol: budesonide-formoterol 200/6, beclometasone-formoterol 100/6: works as reliever and controller
- LABA: salmeterol, formoterol, indacaterol, olodaterol, vilanterol; never alone in asthma
- LAMA: tiotropium, umeclidinium, glycopyrronium, aclidinium
- Combinations: ICS-LABA, LABA-LAMA, triple ICS-LABA-LAMA single inhaler
Asthma (adults, GINA 2026 Track 1)
- Preferred Steps 1-2: as-needed low-dose ICS-formoterol (anti-inflammatory reliever); no daily inhaler needed
- Preferred Step 3: low-dose ICS-formoterol MART (daily + as needed)
- Preferred Step 4: medium-dose ICS-formoterol MART
- Preferred Step 5: add LAMA; refer for phenotyping; biologics (anti-IgE, anti-IL5, anti-IL4R, anti-TSLP)
- Alt Track 2: SABA reliever with ICS each time, or regular ICS / ICS-LABA; ICS-SABA reliever now an option
- Avoid SABA alone: never treat asthma with a SABA only (higher risk of severe attacks and death)
COPD (GOLD)
- Group A: one long-acting bronchodilator; GOLD 2027 prefers a LAMA
- Group B (more symptoms): Preferred LABA + LAMA, ideally one inhaler
- Group E (1 or more exacerbations): LABA + LAMA; consider triple therapy if blood eosinophils 300/µL or more
- Exacerbations on LABA+LAMA: add ICS (triple) if eosinophils 100/µL or more; roflumilast or azithromycin in selected patients
- Biologics: dupilumab or mepolizumab for exacerbation-prone eosinophilic COPD
- Avoid ICS-LABA without LAMA: in COPD; if ICS is needed, use triple therapy
Acute attacks
- Asthma attack: SABA 4-10 puffs by spacer every 20 min for 1 h, or ICS-formoterol extra doses (max 72 mcg formoterol/day); oxygen to SpO2 93-95%
- Oral steroid: prednisolone 40-50 mg daily for 5-7 days (children 1-2 mg/kg, max 40 mg)
- Severe asthma: ipratropium nebs, IV magnesium sulfate 2 g, ICU if not improving
- COPD exacerbation: SABA ± ipratropium, prednisolone 40 mg for 5 days, antibiotics if sputum purulent; oxygen target 88-92%
- Danger signs: cannot speak sentences, SpO2 under 92% (asthma), silent chest, confusion, rising CO2
Inhaler technique
- pMDI: shake, breathe out, seal lips, press and breathe in slowly and deeply, hold 10 s; use a spacer if coordination is poor
- Dry powder inhaler (DPI): do not shake; breathe in fast and deep; never breathe into the device
- Soft mist (Respimat): slow deep breath while pressing
- Check: technique at every visit: most "treatment failure" is wrong technique or poor adherence
- After ICS: rinse mouth and spit to prevent oral thrush and hoarse voice
Side effects & safety
- SABA/LABA: tremor, fast heartbeat, low potassium (high doses)
- LAMA: dry mouth, urinary retention, caution in narrow-angle glaucoma
- ICS: oral thrush, hoarseness; in COPD higher pneumonia risk
- Beta-blockers: non-selective ones can trigger asthma attacks; cardioselective are usually safe in COPD
- NSAIDs / aspirin: can trigger attacks in aspirin-sensitive asthma
- Every COPD patient: stop smoking, vaccines (flu, pneumococcal, COVID-19, RSV), pulmonary rehabilitation
Adult doses and steps; children have separate GINA steps. Always follow local guidelines and the prescriber. Sources: GINA 2026 Strategy Report; GOLD 2026 and 2027 Reports.
Details behind the card
1. What is new?
- GINA 2026: as-needed ICS-formoterol remains the preferred reliever for adults and adolescents; ICS-SABA has been added as a Step 1 option in Track 2, and dosing for AIR and MART has been simplified.
- No SABA-only treatment for asthma at any age, including children.
- GOLD 2026: even one moderate exacerbation now places a patient in group E; blood eosinophils guide ICS use; dupilumab and mepolizumab are recognised add-on biologics.
- GOLD 2027: a LAMA is now the preferred initial treatment for group A, and CT is recommended at least once where available.
2. Asthma vs COPD
| Feature | Asthma | COPD |
|---|---|---|
| Age of onset | Often childhood or young adult | Usually over 40, smoker or biomass exposure |
| Symptoms | Variable, worse at night, triggers | Persistent, slowly progressive breathlessness |
| Airflow limitation | Reversible | Not fully reversible (FEV1/FVC under 0.7 after bronchodilator) |
| Main controller | ICS (with formoterol) | LAMA / LABA bronchodilators |
| ICS role | Essential in all patients | Only if eosinophils high or frequent exacerbations |
3. Counselling checklist
- Show and check inhaler technique; a spacer makes pMDIs work much better.
- Explain reliever vs preventer; with MART one inhaler does both.
- Carry the reliever at all times; seek help if needing it much more than usual.
- Know your triggers: dust, smoke, cold air, pollen, infections; avoid smoking and biomass smoke (chulha).
- Have a written asthma action plan.
4. Special groups
- Children 6-11: low-dose ICS-formoterol MART is an option from Step 3; under 5 years use pMDI with spacer and mask.
- Pregnancy: continue asthma medicines; uncontrolled asthma is more dangerous to the baby than ICS.
- Elderly: choose a device they can use; soft-mist or pMDI with spacer if inspiratory flow is weak.
Remember for exams
- Asthma: never SABA alone; preferred reliever is ICS-formoterol.
- MART = maintenance and reliever therapy with ICS-formoterol (from Step 3).
- COPD: LABA + LAMA for groups B and E; triple if eosinophils 300/µL or more.
- Avoid ICS-LABA without LAMA in COPD.
- Oxygen target: asthma 93-95%, COPD 88-92%.
- Rinse mouth after ICS to prevent thrush.
Sources
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2026.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2026 and 2027 Reports.
- Product information (SmPC) for individual inhalers.
Important: this card is for education and revision. Treatment decisions must follow local guidelines and the treating doctor. More pocket cards: Clinical Pocket Cards
No comments:
Post a Comment